⚠️ JAN 12 – FEB 6 CYBERATTACK: ALL ORDERS REFUNDED • DO NOT PURCHASE UNTIL FURTHER NOTICE • CONTACT support@anubis.estate FOR REFUND STATUS
ApprovedPPI

Omeprazole

Formula Pending

Molecular Mass
N/A
CAS Registry
N/A
Risk Class
LOW
Last Audit
Jan 1, 2024

Research Abstract

PPI medication

We tend to think of Omeprazole as just another antacid, a simple remedy for heartburn. But chemically, it's a proton pump inhibitor (PPI) that intricately manipulates the very fundamental processes of acid secretion in the stomach. Unlike antacids that neutralize existing acid, Omeprazole prevents its formation, acting as a covalent antagonist at the H+/K+ ATPase enzyme system, the final step in the secretion of gastric acid.

Omeprazole's mechanism is both elegant and potent. It selectively targets the H+/K+ ATPase enzyme located in the parietal cells of the stomach lining. Once administered, Omeprazole is absorbed and then converted to its active form in the acidic environment of the parietal cell canaliculi. This active form binds covalently to the cysteine residues on the enzyme, effectively 'turning off' the acid pump. This is akin to a dimmer switch that can be turned down significantly, reducing acid secretion by up to 90%. Pharmacokinetically, Omeprazole has a half-life of approximately 0.5 to 1 hour but its effects last much longer due to this irreversible binding. It is metabolized primarily in the liver via CYP2C19 and CYP3A4 pathways, with notable variability in metabolism based on genetic polymorphisms affecting CYP2C19.

Clinically, Omeprazole is approved for the treatment of gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome, and peptic ulcer disease. Off-label, it has been used for conditions like Barrett's esophagus and laryngopharyngeal reflux. Its safety profile is generally favorable, but long-term use has been associated with potential risks such as vitamin B12 deficiency, hypomagnesemia, and increased susceptibility to gastrointestinal infections. Drug interactions can occur with medications metabolized by CYP2C19, including clopidogrel, where Omeprazole may reduce its effectiveness. Current regulatory status remains stable, with no black box warnings, but ongoing research continues to explore its role in cancer prevention and treatment of other acid-related disorders. In research settings, its rapid onset and potent effect make it a valuable tool for studies requiring controlled gastric acid suppression.

Acquisition Protocol

Authorized research personnel may request deployment of this compound for laboratory analysis.

Primary Vectors

TherapeuticClinical Research

Nomenclature

Omeprazole

Reference Material

  1. [1] Sachs G et al. • The pharmacology of the proton pump inhibitor omeprazole • Annual Review of Pharmacology and Toxicology. 1995;35:277-305.
  2. [2] FDA • Omeprazole Label • 2020.
  3. [3] Lai KC et al. • Long-term use of proton-pump inhibitors and vitamin B-12 deficiency: a review of the evidence • The American Journal of Gastroenterology. 2013;108:1030-1035.